1. Improved Outcome in Patients with Chronic Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Over the Past 25 Years: A Single-Center Experience 
Alexandra Boehm, Barbara Walcherberger, Wolfgang R. Sperr, Stefan Wöhrer, Karin Dieckmann, Agathe Rosenmayr, Elisabeth Pernicka, Gottfried Fischer, Nina Worel, Gerlinde Mitterbauer, Ilse Schwarzinger, M. Mitterbauer, Oskar A. Haas, Klaus Lechner, W. Hinterberger, Peter Valent, Hildegard T. Greinix, Werner Rabitsch, Peter Kalhs 
Biology of Blood and Marrow Transplantation 
Volume 17, Issue 1, Pages (January 2011)
DOI: /j.bbmt
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Probability of overall survival (OS) for all CML patients (n = 175) performed in the years , , and (P <.05).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Probability of overall survival (OS) for all CML patients (n = 175) according to the phase of the disease (P < .05).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Cumulative incidence probability of overall survival (OS) for CML patients with (n = 32) or without (n = 143) imatinib prior to HCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Probability of overall survival (OS) for CML patients with bone marrow derived stem cells (n = 131) or peripheral blood derived stem cells (n = 44).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions